Skip to main content

Press releases

Go back

Progress in clinical development for Alzheimer´s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator

Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease

Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator

Galimedix Therapeutics presents further scientific data showing disease-modifying potential of oral GAL-201 in Alzheimer’s disease as well as beneficial effects on synaptic function and neuroimmunomodulation at AD/PD™ 2025

Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD™ 2025 Conference

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD

Galimedix Therapeutics initiates Phase 1 study with oral small molecule, GAL-101, an amyloid beta (Aβ) aggregation modulator

Galimedix Therapeutics establishes Scientific Advisory Board of renowned retina experts as company prepares to enter Phase 2 clinical study with GAL-101

Galimedix is proud to report that the inventor of the company’s groundbreaking technology for the treatment of Alzheimer’s disease and our esteemed co-founder, Prof. Ehud Gazit, has been honored with Germany’s prestigious Meitner-Humboldt Research Award

Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024

1
2
3